A recent study of mRNA vaccination, for example, indicates that breakthrough COVID-19 is associated with lower serologic titers of S/RBD-specific IgA, but not IgG22, thus emphasizing the need to include IgA in vaccine immunogenicity assessments. The gene discussed is CD79A; the disease is COVID-19.